Skip to content

Research of Precision Diagnosis and Treatment Based on Multi-omics in Advanced Laryngeal and Pharyngeal Cancer

Research of Precision Diagnosis and Treatment Based on Multi-omics in Advanced Laryngeal and Pharyngeal Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059671
Enrollment
Unknown
Registered
2022-05-06
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

Sponsors

Beijing Tongren Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with advanced throat cancer (local tumor T2-4a, any N); 2. Age 18-75 years; 3. Newly treated patients (primary, without history of surgery, radiotherapy and chemotherapy); 4. KPS score 80 points and above; 5. Blood picture, heart, lung, liver, kidney and other major organs are basically normal. WBC=3.5 × 109/LANC=1.5 × 109/L PLT=100 × 109/L, Hb = 80g/L, plasma total bilirubin = 1.5 × Upper limit of normal value, ALT, AST or AKP = 2.5 × Upper limit of normal value, urea nitrogen, creatinine = 1.25 × Upper limit of normal value; 6. Complete enhanced CT and endoscopic examination of neck and chest before enrollment; 7. Pathological examination before enrollment (degree of differentiation, immunological index - Ki-67, EGFR, HPV); 8. Sign the informed consent form with good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients with distant metastasis; 2. Patients who can be removed by minimally invasive surgery such as laser under the support laryngoscope; 3. Have uncontrollable seizures, central nervous system disorder or loss of insight due to mental illness; 4. Serious uncontrollable infection; 5. Those with major organ dysfunction (including heart, lung, liver, kidney, etc.); 6. Those who cannot tolerate general anesthesia; 7. Other malignant tumors at the same time or within two years.

Design outcomes

Primary

MeasureTime frame
Overall survival;

Secondary

MeasureTime frame
Recurrence-free survival;

Countries

China

Contacts

Public ContactJugao Fang

Beijing Tongren Hospital, Capital Medical University

fangjugao2@ccmu.edu.cn+86 18811612211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026